Literature DB >> 19491279

Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer.

Feng Qian1, Jeannine Villella, Paul K Wallace, Paulette Mhawech-Fauceglia, Joseph D Tario, Christopher Andrews, Junko Matsuzaki, Danila Valmori, Maha Ayyoub, Peter J Frederick, Amy Beck, Jianqun Liao, Richard Cheney, Kirsten Moysich, Shashikant Lele, Protul Shrikant, Lloyd J Old, Kunle Odunsi.   

Abstract

It has been reported that levo-1-methyl tryptophan (L-1MT) can block indoleamine-2,3-dioxygenase (IDO) expressed by human dendritic cells (DC), whereas dextro-1-methyl tryptophan (D-1MT) is inefficient. However, whether L-1MT or D-1MT can efficiently reverse IDO-induced arrest of human T-cell proliferation has not been clarified. Here, we show a marked immunosuppressive effect of IDO derived from INDO-transfected 293 cell, IDO+ ovarian cancer cells, and monocyte-derived DCs on CD4+ Th1 cells, CD8+ T cells, and natural killer cells derived from peripheral blood, ascites, and tumors of ovarian cancer patients. We found that, whereas L-1MT and D/L-1MT can restore proliferation of tumor-derived and peripheral blood T-cell subsets, D-1MT does not effectively restore IDO-induced arrest of T-cell proliferation. Although D-1MT inhibited kynurenine production at high concentrations, L-1MT was more effective in abrogating kynurenine generation and tryptophan depletion, whereas tryptophan was completely depleted by IDO even in the presence of high amounts of D-1MT. Together, the results indicate that, whereas the generation of tryptophan metabolites (kynurenines) by IDO is important in mediating suppression of T-cell proliferation, the degree to which tryptophan depletion is restored by 1MT is also critical in overcoming IDO-induced arrest of T-cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19491279     DOI: 10.1158/0008-5472.CAN-08-2106

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

Review 1.  Tumor infiltrating lymphocytes in ovarian cancer.

Authors:  Phillip P Santoiemma; Daniel J Powell
Journal:  Cancer Biol Ther       Date:  2015-04-20       Impact factor: 4.742

Review 2.  Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer.

Authors:  Thinle Chodon; Amit A Lugade; Sebastiano Battaglia; Kunle Odunsi
Journal:  Hematol Oncol Clin North Am       Date:  2018-10-01       Impact factor: 3.722

Review 3.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 4.  Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege.

Authors:  Lei Huang; Babak Baban; Burles A Johnson; Andrew L Mellor
Journal:  Int Rev Immunol       Date:  2010-04       Impact factor: 5.311

Review 5.  Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.

Authors:  Annie A Wu; Virginia Drake; Huai-Shiuan Huang; ShihChi Chiu; Lei Zheng
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

Review 6.  Immunotherapy in ovarian cancer.

Authors:  K Odunsi
Journal:  Ann Oncol       Date:  2017-11-01       Impact factor: 32.976

7.  Inhibition of indoleamine 2,3-dioxygenase activity by levo-1-methyl tryptophan blocks gamma interferon-induced Chlamydia trachomatis persistence in human epithelial cells.

Authors:  Joyce A Ibana; Robert J Belland; Arnold H Zea; Danny J Schust; Takeshi Nagamatsu; Yasser M AbdelRahman; David J Tate; Wandy L Beatty; Ashok A Aiyar; Alison J Quayle
Journal:  Infect Immun       Date:  2011-09-12       Impact factor: 3.441

Review 8.  Cancer prevention and therapy through the modulation of the tumor microenvironment.

Authors:  Stephanie C Casey; Amedeo Amedei; Katia Aquilano; Asfar S Azmi; Fabian Benencia; Dipita Bhakta; Alan E Bilsland; Chandra S Boosani; Sophie Chen; Maria Rosa Ciriolo; Sarah Crawford; Hiromasa Fujii; Alexandros G Georgakilas; Gunjan Guha; Dorota Halicka; William G Helferich; Petr Heneberg; Kanya Honoki; W Nicol Keith; Sid P Kerkar; Sulma I Mohammed; Elena Niccolai; Somaira Nowsheen; H P Vasantha Rupasinghe; Abbas Samadi; Neetu Singh; Wamidh H Talib; Vasundara Venkateswaran; Richard L Whelan; Xujuan Yang; Dean W Felsher
Journal:  Semin Cancer Biol       Date:  2015-04-10       Impact factor: 15.707

Review 9.  HLA-G regulators in cancer medicine: an outline of key requirements.

Authors:  Ines Zidi; Nidhal Ben Amor
Journal:  Tumour Biol       Date:  2011-07-27

10.  Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth.

Authors:  Céline A Blache; Edwin R Manuel; Teodora I Kaltcheva; Andrea N Wong; Joshua D I Ellenhorn; Bruce R Blazar; Don J Diamond
Journal:  Cancer Res       Date:  2012-10-22       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.